MyRent is a cloud-based system for managing tenants and rent payment. Our customers are businesses renting out apartments in Norway. MyRent has been running since 2012, and with help from a customized CRM system, we started getting customers early on. Today handle about 28 Million NOK in monthly payments for our customers. Our goal is to get this platform out in Scandinavia, after building the bases in Norway.

Rektor AS er en totalleverandør innen vareproduksjon, e-commerce, logistikk, markedsføring og salg.Vi samarbeider tett med start-ups, kunstnere/artister, idéskapere og ulike selskaper for å skape ikoniske brands og engasjerende opplevelser som knytter mennesker til merkevarer og organisasjoner. Våre kunder er blant annet Alan Walker, Karpe, Justin Bieber, SHM, Handelshøgskolen BI og mange fler..Enten du ønsker å samarbeide med oss som totalleverandør eller kun benytte deg av enkelte tjenester, er vi her for å gjøre din hverdag enklere og så sømløs som mulig.

CardiNor AS er et norsk bioteknologiselskap etablert for å håndtere kommersialiseringen av secretoneurin, en ny biomarkør test for hjertekar sykdom. Vår innovasjon er en ny og proprietær hjertekar test – secretoneurin. Secretoneurin er vist å ha sterk prognostisk nytteverdi hos pasienter med hjertesvikt, og den har et særskilt stort potensial hos pasienter med hjerterytmeforstyrrelser (arytmi). Hjertekar sykdom er fortsatt den viktigste dødsårsaken i verden i dag. Ingen av de kjent og etablerte biomarkørene for hjertekar sykdom er til særlig hjelp i valg av medisinske, og eller kirurgiske behandlingsmetoder for å forhindre livstruende hjerterytmeforstyrrelser. Selskapet utvikler nå en brukervennlig forskningstest for å måle secretoneurin blod som vil markedsført og solgt gjennom et nettverk av distributører i Europa og USA. Dette etterfulgt av introduksjonen av et CE-merket produkt for klinisk bruk i Europa og regulatorisk godkjenning i USA. CardiNor-ledelsen har inngående kunnskap om og erfaring fra bioteknologi og diagnostisk industri som dekker hele livssyklus fra oppstart til exit. CardiNor samarbeider med verdensledende akademiske institusjoner og opinionsledere og industri i å utvikle og dokumentere biomarkør testen.

Otivio’s main product, FlowOx™, is addressing chronic wounds with focus on peripheral arterial disease (PAD), which is a serious condition leading to pain, chronic wounds and in many cases amputation and mortality. The patient population is very large and increasing. There are limited adequate treatment options offered to the patients aside from surgical interventions. FlowOx™ is a non-invasive product intended for home use. Long-term patient testing in more than 50 patients documents increased blood flow, reduced pain and wound healing. FlowOx™ is CE marked. In fourth quarter 2017 had its commercial break-through through sales of FlowOx to public customers.

Medsensio will develop educational, clinical, and monitoring tools by analyzing medical data using machine learning and statistics. Our first project is developing an auscultation learning tool for students. Students will be able to verify their own interpretations of lung sounds using our machine-learning technology

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

Nanook is a global movement of more than 2400 local travel experts committed to sharing amazing experiences and insider knowledge. Being a partner of Nanook not only require high quality, but we also have non-negotiable rules of local ownership and responsibility towards nature and local communities.

Flexfit.no er et hjertebarn som ble etablert av treningsentusiaster som alltid så etter nye og bedre metoder å trene på. Gjennom årene har vi utviklet treningsutstyr i samarbeid med profesjonelle utøvere, for bedre og mer effektiv trening. Våre Flexfit løftebelter- og grips er anerkjent som de beste i treningsmiljøet og er produkter som kun selges igjennom vår nettbutikk. FlexFit.no er kjent som en spesialbutikk for salg av kvalitetsprodukter til crossfit miljøet, men med årene blitt til en nettbutikk med produktfokus på trening, helse, kosthold og livsstil. Men fortsatt vårt gode produktutvalg innen crossfit.

LangO is changing the way companies deliver English language training to their employees online. We do this through a blended learning solution; a combination of live virtual lessons (Group Live Lessons and One-to-One) complemented by our on-demand micro-learning activities. Our responsive web app brings in the best-qualified teachers from around the world, custom-made LangO lesson content based on client's needs, and a scalable tech stack enabling employees to learn effectively on any device, at any time.

Nordic Electrofuel offers a solution for the rapid transition from fossil to renewable electrical energy for all transport sectors. It is based on the conversion of renewable electric energy into liquid electro-fuels that can be as easily transported, stored, and used as conventional fossil hydrocarbons. It also provides a good solution to distribute and store stranded electrical energy. PTL (Power To Liquid) has been considered too expensive, but with the low electricity price in Norway and new efficient processing and upgrading solutions, it has become commercially feasible. Electrification of transportation is required to avoid catastrophic climate change. Battery- or cable-electric solutions are not feasible for transport like aviation and long-distance marine transport. Liquid energy carriers such as biofuels are desperately needed but limited. The fuel is free of sulfur and can therefore be used maritime industry as a fuel after 2022. The fuel emits much fewer particles and aromatics than conventional fossil fuel, so it also solves the local pollution problem. Competitive advantages: • Norway’s low electricity price from hydro and lately also wind power. • 20 - 30 % lower electricity consumption than with existing technology • Lower production price than advanced biofuels • Agreements in place for a site at Herøya, which has all utilities (cooling water, cheap renewable electricity, etc.) and processing expertise available. • About the same source to shaft efficiency as hydrogen, but with much lower total CAPEX due to no investment in distribution systems and engines.

Excitus is set up to develop, manufacture and sell medical suction products based on its revolutionary, patent-pending mobile suction platform. Products will span from professional hand-held tools for paramedics to consumer devices in a private home and stored together with the defibrillator at supermarkets, stadiums, etc. The platform enables a higher survival rate at cardiac arrests, yet at the same time, it provides a razor/razorblade business model unseen in this area.

Ecomerden is a complete producer of semi-closed cage systems for Aquaculture founded in 2012. With over 25 years of experience in delivering technology in the aquaculture industry, we started developing Ecomerden, a European patented semi-closed system for the lice-free production of fish. By 2015 the first cage was installed in Solund. Sogn & Fjordane. Here we have produced lice-free post-smolt of Atlantic salmon (90 grams-1kg) for 2 years with groundbreaking results. Using Ecomerden as a combination in the production line of the fish not only prevents lice pressure but also makes a more robust smolt ready for the open cages. With the results so far showing that the technology and biology are working, the company is now ready for commercialization.

"Transparently Norwegian"​ We carefully select guaranteed Norwegian products, ship them via our own "digital highway of trust"​ to ourselves (in China) and sell them directly to end-users in the world (starting with China) through our own e-Commerce platform (and soon in our own retail stores). We are in business, we control the whole value chain, we do it differently and our concept can't be copied by big American tech or food companies. We also represent business opportunities for other companies.

Halify AS operates on markets within the field of urban spatial area management, with a specific focus on Intelligent Transport Systems (ITS) and urban mobility. We have supplied solutions for Horizon2020-funded projects (VICINITY, CrossMove, BIG IoT), and received support from the Research Council of Norway on projects like Komét and Sparkling, and cooperated with the NCE environment in Horten and Oslo. We are active within several consortiums and part of the Smart Cities Norway network, the ENIT network, and ITS Arena. We have developed solutions for calculating and visualizing the environmental impact made by the transport industry on Norwegian municipalities, and take pride in visualizing difficult concepts and results in a way that is easy to convey.

Fishency Innovation can give access to the entire salmon industry to affordable equipment to count automatically sea lice in the cage. Monitoring sea lice is the key to controlling them, it is access to good decision support for optimized treatments and to a reliable tool to measure the efficiency of preventive measures and existing treatments. Today, sea lice are counted manually over 20 fish, every week, in each cage. It is labor-demanding, and the collected data are not reliable. Sustainability starts with good data.